We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
-36.21%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$42.4M
AUM Growth
-$90.1M
(-68%)
Cap. Flow
-$62.9M
Cap. Flow
% of AUM
-148.27%
Top 10 Holdings %
Top 10 Hldgs %
96.96%
Holding
13
New
1
Increased
6
Reduced
5
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KZR
Kezar Life Sciences
KZR
|
+$1.24M |
| 2 |
ADVM
Adverum Biotechnologies
ADVM
|
+$743K |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$644K |
| 4 |
Precision BioSciences
DTIL
|
+$508K |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$320K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
+$65.9M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$285K |
| 3 |
BLUE
bluebird bio
BLUE
|
+$151K |
| 4 |
Ovid Therapeutics
OVID
|
+$52.3K |
| 5 |
Corvus Pharmaceuticals
CRVS
|
+$25.1K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.95% |
| 2 | Communication Services | 6.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORTX
1
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $22.3M | 52.57% |
296,227
+378
| +0.1% | +$43.5K |
|
|
2
Precision BioSciences
DTIL
$232M
| $5.67M | 13.37% |
31,352
+1,940
| +7% | +$508K |
|
|
LVGO
3
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $2.57M | 6.05% |
90,000
-2,546,640
| -97% | -$65.9M |
|
|
4
Ovid Therapeutics
OVID
$572M
| $2.47M | 5.82% |
828,413
-15,518
| -2% | -$52.3K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $2.1M | 4.96% |
36,000
+10,000
| +38% | +$644K |
|
|
KZR
6
DELISTED
Kezar Life Sciences
KZR
| $2M | 4.72% |
45,889
+30,463
| +197% | +$1.24M |
|
7
Ultragenyx Pharmaceutical
RARE
$2.59B
| $1.75M | 4.12% |
39,362
+862
| +2% | +$44.8K |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $805K | 1.9% |
15,750
-4,250
| -21% | -$285K |
|
|
9
Corvus Pharmaceuticals
CRVS
$1.24B
| $768K | 1.81% |
364,132
-6,175
| -2% | -$25.1K |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $703K | 1.66% |
15,000
+5,000
| +50% | +$320K |
|
|
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
| $623K | 1.47% |
+6,375
| New | +$743K |
|
12
Cogent Biosciences
COGT
$6.44B
| $389K | 0.92% |
235,201
| – | – |
|
|
BLUE
13
DELISTED
bluebird bio
BLUE
| $276K | 0.65% |
463
-155
| -25% | -$151K |
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q1 2020 Portfolio in Review
As of Q1 2020, CHI Advisors held 13 positions worth $42.4M, down 68% from $133M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
CHI Advisors withdrew a net $62.9M in Q1 2020, reducing 5 holdings. Its largest reduction was Livongo Health, Inc. Common Stock, cutting an estimated $65.9M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 50% a quarter earlier, followed by Communication Services.
Against the trend, CHI Advisors opened a new position in Adverum Biotechnologies worth $623K.
- CHI Advisors's largest Q1 2020 buy was Adverum Biotechnologies: 6,375 shares worth $623K.
- CHI Advisors added most to Kezar Life Sciences in Q1 2020, an estimated $1.24M increase.
- CHI Advisors's biggest Q1 2020 reduction was Livongo Health, Inc. Common Stock, cutting an estimated $65.9M.
- CHI Advisors's ten largest holdings make up 97% of its $42.4M portfolio in Q1 2020.
- CHI Advisors opened 1 new position and closed 0 in Q1 2020.
- CHI Advisors's portfolio value fell 68% quarter-over-quarter to $42.4M.
Based on CHI Advisors's 13F filing for Q1 2020, filed 14 May 2020.